Pseudomyxoma Peritonei clinical trials at UCSF
1 research study open to eligible people
Pseudomyxoma Peritonei is a rare cancer that starts in the appendix. UCSF is recruiting for a clinical trial that will test a drug called SGN-STNV to see if it is safe for patients with solid tumors. The study will determine what side effects, if any, the drug may cause.
A Study of SGN-STNV in Advanced Solid Tumors
open to eligible people ages 18 years and up
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.
San Francisco, California and other locations
Our lead scientists for Pseudomyxoma Peritonei research studies include Pamela Munster.
Last updated: